World’s first stem cell trial on heart failure is successful. Angioblast Systems Inc has announced the successful clinical trial to use allogeneic adult stem cells obtained from an unrelated, universal donor to treat patients with congestive heart failure.

Safety data from the first seven patients enrolled in the trial by Angioblast at medical centers in Arizona, California, and Minnesota were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington D.C.Angioblast’s Revascor(TM) adult stem cells are delivered to damaged areas of the heart by a minimally invasive cardiac catheterization procedure performed under local anesthesia while the patient is awake. Patients undergoing the procedure are released from the hospital within 24 hours.

The study can be a ray of hope for millions of Americans. There are currently five million people in the United States living with heart failure, and trends indicate that the incidence of heart failure has not declined in the last 20 years. As the number of people living in the United States with cardiovascular disease continues to rise at a rate of 550,000 new cases annually, the health and economic burden of this disease will greatly impact the population’s health status. It is estimated that thehealthcare cost to care for heart failure patients is in excess of $29 billion per year.

About Angioblast Systems, Inc.
It is a private New York City-based biotechnology company committed to the development of novel treatments for cardiac, vascular, and eye conditions. Angioblast’s lead products are based on commercialization of a unique adult stem cell technology capable of regulating blood vessel growth critical for the treatment of ischemic heart disease of adult and macular degeneration/diabetic eye disease. Angioblast’s focus is to progress through clinical trials and regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Angioblast has the worldwide assignment of rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction, culture expansion and enablementMesenchymal Precursor Cells (MPCs).

Source: MarketWatch